FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381714922> ?p ?o ?g. }

• W4381714922 abstract "Clinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the clinical effects of Crizotinib. To combat drug resistance, some novel 2-aminopyridine derivatives were designed rationally based on molecular simulation, then synthesised and subjected to biological test. The preferred spiro derivative C01 exhibited remarkable activity against CD74-ROS1G2032R cell with an IC50 value of 42.3 nM, which was about 30-fold more potent than Crizotinib. Moreover, C01 also potently inhibited enzymatic activity against clinically Crizotinib-resistant ALKG1202R, harbouring a 10-fold potency superior to Crizotinib. Furthermore, molecular dynamic disclosed that introducing the spiro group could reduce the steric hindrance with bulky side chain (Arginine) in solvent region of ROS1G2032R, which explained the sensitivity of C01 to drug-resistant mutant. These results indicated a path forward for the generation of anti Crizotinib-resistant ROS1/ALK dual inhibitors." @default.
• W4381714922 created "2023-06-24" @default.
• W4381714922 creator A5009831782 @default.
• W4381714922 creator A5011587113 @default.
• W4381714922 creator A5012023359 @default.
• W4381714922 creator A5013412405 @default.
• W4381714922 creator A5023632317 @default.
• W4381714922 creator A5042262404 @default.
• W4381714922 creator A5047722858 @default.
• W4381714922 creator A5050018283 @default.
• W4381714922 creator A5051366494 @default.
• W4381714922 creator A5056689090 @default.
• W4381714922 creator A5071599697 @default.
• W4381714922 creator A5075447034 @default.
• W4381714922 creator A5089041639 @default.
• W4381714922 date "2023-06-22" @default.
• W4381714922 modified "2023-10-12" @default.
• W4381714922 title "Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1^G2032R and ALK^G1202R" @default.
• W4381714922 cites W1970564438 @default.
• W4381714922 cites W1975580333 @default.
• W4381714922 cites W1976161355 @default.
• W4381714922 cites W1998371249 @default.
• W4381714922 cites W2008167816 @default.
• W4381714922 cites W2017757358 @default.
• W4381714922 cites W2019611572 @default.
• W4381714922 cites W2038586807 @default.
• W4381714922 cites W2046929648 @default.
• W4381714922 cites W2052546787 @default.
• W4381714922 cites W2055402151 @default.
• W4381714922 cites W2061820313 @default.
• W4381714922 cites W2065838297 @default.
• W4381714922 cites W2067174909 @default.
• W4381714922 cites W2077769347 @default.
• W4381714922 cites W2103447891 @default.
• W4381714922 cites W2111254482 @default.
• W4381714922 cites W2113327188 @default.
• W4381714922 cites W2122528459 @default.
• W4381714922 cites W2123336268 @default.
• W4381714922 cites W2127129900 @default.
• W4381714922 cites W2130488043 @default.
• W4381714922 cites W2133668831 @default.
• W4381714922 cites W2147993766 @default.
• W4381714922 cites W2161605421 @default.
• W4381714922 cites W2168691181 @default.
• W4381714922 cites W2208535430 @default.
• W4381714922 cites W2212897984 @default.
• W4381714922 cites W2460269356 @default.
• W4381714922 cites W2465928371 @default.
• W4381714922 cites W2466915283 @default.
• W4381714922 cites W2482427906 @default.
• W4381714922 cites W2607398004 @default.
• W4381714922 cites W2765831845 @default.
• W4381714922 cites W2784414491 @default.
• W4381714922 cites W2796923356 @default.
• W4381714922 cites W2905492903 @default.
• W4381714922 cites W2955817892 @default.
• W4381714922 cites W3134566625 @default.
• W4381714922 cites W4206966563 @default.
• W4381714922 doi "https://doi.org/10.1080/14756366.2023.2227779" @default.
• W4381714922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37349867" @default.
• W4381714922 hasPublicationYear "2023" @default.
• W4381714922 type Work @default.
• W4381714922 citedByCount "0" @default.
• W4381714922 crossrefType "journal-article" @default.
• W4381714922 hasAuthorship W4381714922A5009831782 @default.
• W4381714922 hasAuthorship W4381714922A5011587113 @default.
• W4381714922 hasAuthorship W4381714922A5012023359 @default.
• W4381714922 hasAuthorship W4381714922A5013412405 @default.
• W4381714922 hasAuthorship W4381714922A5023632317 @default.
• W4381714922 hasAuthorship W4381714922A5042262404 @default.
• W4381714922 hasAuthorship W4381714922A5047722858 @default.
• W4381714922 hasAuthorship W4381714922A5050018283 @default.
• W4381714922 hasAuthorship W4381714922A5051366494 @default.
• W4381714922 hasAuthorship W4381714922A5056689090 @default.
• W4381714922 hasAuthorship W4381714922A5071599697 @default.
• W4381714922 hasAuthorship W4381714922A5075447034 @default.
• W4381714922 hasAuthorship W4381714922A5089041639 @default.
• W4381714922 hasBestOaLocation W43817149221 @default.
• W4381714922 hasConcept C104317684 @default.
• W4381714922 hasConcept C114851261 @default.
• W4381714922 hasConcept C121608353 @default.
• W4381714922 hasConcept C126322002 @default.
• W4381714922 hasConcept C143065580 @default.
• W4381714922 hasConcept C185592680 @default.
• W4381714922 hasConcept C2775999482 @default.
• W4381714922 hasConcept C2776232967 @default.
• W4381714922 hasConcept C2778347629 @default.
• W4381714922 hasConcept C2779422266 @default.
• W4381714922 hasConcept C2779634585 @default.
• W4381714922 hasConcept C2780035454 @default.
• W4381714922 hasConcept C2781182431 @default.
• W4381714922 hasConcept C54355233 @default.
• W4381714922 hasConcept C55493867 @default.
• W4381714922 hasConcept C71240020 @default.
• W4381714922 hasConcept C71924100 @default.
• W4381714922 hasConcept C86803240 @default.
• W4381714922 hasConcept C98274493 @default.
• W4381714922 hasConceptScore W4381714922C104317684 @default.
• W4381714922 hasConceptScore W4381714922C114851261 @default.
• W4381714922 hasConceptScore W4381714922C121608353 @default.

• next